Infinant Health
2121 2nd Street
Suite B107
Davis
California
95618
United States
Website: https://infinanthealth.com/
23 articles about Infinant Health
-
Last Participant Enrolled in Study of Infant Microbiome and Immune Health
2/15/2023
Infinant Health, Inc, a company focused on improving infant health through the gut microbiome, today announced the enrollment of the final participant in a study focused on the infant microbiome and immune health.
-
Evolve Biosystems becomes Infinant Health
10/3/2022
Infinant Health ("Infinant Health" or the "Company"), a privately-held company focused on changing the trajectory of human health, one baby at a time, and previously known as Evolve Biosystems, proudly announces the bold transformation of the brand and strategic path forward.
-
Investors Continue to Support Breakthrough Research on Infant Gut Health
5/25/2021
Evolve BioSystems, Inc., a privately-held leading microbiome company, announced the second and final close of its Series D round of funding exceeding $65 million, led by investors Cargill and Manna Tree.
-
Evolve BioSystems, Inc. Announces the Use of Activated B. infantis EVC001 by International Consortium to Study the Prevention of Type 1 Diabetes in Children
3/11/2021
Evolve BioSystems, Inc. today announces that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes (T1D) in genetically predisposed children.
-
Evolve BioSystems Announces Major Strategic Investment from Cargill and Manna Tree to Support Innovative Probiotic That Dramatically Improves Infant Gut Health
2/8/2021
Evolve BioSystems announced today that it completed a substantial first close in a $55 million Series D round of funding, led by Cargill, the global food, agricultural, financial and industrial products company and Manna Tree, an investment firm committed to improving human health.
-
Evolve BioSystems, Inc. announces Dr. Minhthy Nguyen as Senior Vice President of Research & Development, further advancing its position as the leader in infant gut health
7/28/2020
Evolve BioSystems announced today that Dr. Minhthy Nguyen , PhD, has joined the company as Senior Vice President, Research & Development. Dr. Nguyen joins the company in anticipation of the pending announcement of positive results from several large clinical studies, positioning the company for a material leap forward in the infan
-
Infant Fecal pH Revealed as a Critical Indicator of Infant Gut Health and Resistance against Gut Pathogen Invasion
4/9/2020
Updated Infant Fecal pH Range Identifies Deficiency of Beneficial Bacteria in Infant Gut Microbiome
-
Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis
3/26/2020
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis.
-
RB and Evolve BioSystems Team Up to Advance Infant Gut Health
12/5/2019
RB and Evolve BioSystems announce a partnership in the sale of Evivo®, Evolve BioSystems' infant probiotic.
-
Evolve BioSystems And The Regents Of The University Of California Jointly File Patent Infringement Complaint Against Abbott Laboratories Regarding Infant Probiotic
9/30/2019
Evolve BioSystems and the Regents of the University of California have jointly filed and served a patent infringement complaint against Abbott Laboratories.
-
Intestinal Inflammation in Infants Dramatically Reduced with Bifidobacterium infantis
9/10/2019
University of California, Davis Study Shows up to 98% Reduction of Intestinal Inflammation Markers Linked to Colic, Eczema, Asthma and Diabetes
-
Novel Probiotic Strain Dramatically Reduces Antibiotic Resistance In Infants
8/14/2019
Breakthrough Study Reveals Activated B. infantis EVC001 as the First Infant Probiotic to Be Effective in the Fight Against Global Health Epidemic
-
First-Ever Rapid Response Test for Levels of Bifidobacterium in Baby's Gut Microbiome
9/20/2018
Evivo Stool Test Prototype Provides Clear Window into Infant Gut Health
-
Significant Reduction in Pathogenic Gut Bacteria Lowers Potential for Infection Risk in Infants Fed B. infantis EVC001
7/18/2018
Evolve BioSystems Demonstrates 93 Percent Drop in Common Pathogens such as E. coli, C. difficile
-
Evolve BioSystems Announces $40 Million Series C Financing to Expand its Flagship Infant Probiotic Product Evivo
6/13/2018
Bill & Melinda Gates Foundation, Li Ka Shing Foundation Lead New Funding Round to Expand Groundbreaking Progress in Restoring Infant Gut Microbiome and to Lay a Global Foundation for Long-Term Nutritional and Immune Health
-
Evolve BioSystems Partners With King’s College London to Resolve Gut Dysbiosis in C-Section Delivered Infants
2/1/2018
The study will investigate the impact of dietary B. infantis EVC001, combined with breastfeeding, in restoring intestinal Bifidobacterium in infants delivered by Caesarean-section, a known cause of infant gut dysbiosis.
-
Evolve BioSystems' Activated B. infantis EVC001 Demonstrates Substantial and Persistent Remodeling of the Infant Gut Microbiome
12/6/2017
The study showed that providing dietary B. infantis EVC001 resulted in rapid, substantial, and persistent remodeling of the gut microbiome in breastfed infants.
-
Evolve BioSystems' Evivo Gains Health Canada Approval, Providing First International Expansion Opportunity
10/30/2017
The license, granted by Health Canada, states that Evivo is safe to give once a day to babies under 1 year of age.
-
Evolve BioSystems Announces Timothy B. Brown As New CEO, David Kyle Named Executive Chairman And Chief Scientific Officer
8/1/2017
-
Evolve BioSystems Release: Evivo Protects Babies From The Inside Out
7/12/2017